Association between Imaging Glymphatic Dysfunction Markers and Clinical Symptoms in Progressive Supranuclear Palsy
Objective: This study aims to explore possible glymphatic dysfunction using diffusion tensor image analysis along the perivascular space (DTI-ALPS) in patients with progressive supranuclear palsy…Brain Target Engagement and Pharmacokinetic-Enzyme Occupancy (PK-EO) Relationship of FNP-223: A Novel Oral OGA Inhibitor for Progressive Supranuclear Palsy – Phase 1 PET Study
Objective: To determine the brain O-GlcNAcase (OGA) occupancy, following a single oral dose of FNP-223 (formerly ASN90) and to determine PK-EO relationship. Background: Preclinical evidence…Clinical subtypes and Radiological patterns in Progressive supranuclear palsy: A Prospective study
Objective: To subclassify Progressive supranuclear palsy (PSP) into cortical and subcortical typesTo identify the clinical and radiological correlation in PSP Background: The 2017 International Parkinson…Connectome of Pathology Stages of Progressive Supranuclear Palsy
Objective: Find the relations between normative FC and seed-to-seed correlations in pathological tau load. Model the FC maps for twelve patients, using post-mortem tau pathology…Enhancing the differential diagnosis of atypical parkinsonian syndromes through a structured clinical acrostic
Objective: To develop a structured clinical acrostic for the differential diagnosis of atypical Parkinsonian syndromes. Background: The diagnosis of atypical parkinsonian syndromes (APS), including dementia…Exploring The Correlation of Neuroimaging, Molecular and Electrophysiological Biomarkers in Patients with Progressive Supranuclear Palsy – Richardson Type
Objective: To correlate blood and electrophysiological biomarkers in Progressive Supranuclear Palsy – Richardson’s type (PSP-RS) patients with brain structural alterations using neuromorphometry. Background: Various biomarkers, including…The Radiographic Overlap Between Normal Pressure Hydrocephalus (NPH) and Progressive Supranuclear Palsy (PSP): When Looks Can Be Deceiving
Objective: To demonstrate the overlap on radiographic metrics between NPH and PSP. Background: The neuroradiological hallmark of NPH is non-obstructive ventriculomegaly (Evans’ index (EI) >0.3).…Retention & Safety in a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo (TOPAZ) in Persons with Neurodegenerative Parkinsonism (NDP)
Objective: To assess retention and safety in the ongoing TOPAZ trial, NCT03924414 Background: People with NDP face a four-fold increased fracture risk, yet preventive treatment…A Quantitative Systems Disease Model for Progressive Supranuclear Palsy.
Objective: Developing a computer model integrating the PSP pathology to support clinical trial for new disease-modifying therapies Background: Progressive Supranuclear Palsy is a fast progressing…Multimodal imaging Integrating 18F-APN-1607 and 18F-FP-DTBZ PET in Progressive Supranuclear Palsy
Objective: To identify the regions with sensitive tau deposition for differentiating progressive supranuclear palsy (PSP) from healthy controls. Additionally, to explore the combination of 18F-APN-1607…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 42
- Next Page »